Purple Book reference family · 351(a) biologic
amivantamab and hyaluronidase-lpuj (Rybrevant Faspro)
amivantamab and hyaluronidase-lpuj is an FDA-licensed reference biologic from Janssen Biotech, Inc..
351(a) biologicBLA 761484 Janssen Biotech, Inc.
Biosimilars
0
Interchangeables
0
Listed patents
0
Reference approved
2026
Reference product
Originator biologic
351(a)BLA 761484
Rybrevant Faspro amivantamab and hyaluronidase-lpuj
Janssen Biotech, Inc.
View full reference-product record- Approved
- Marketing
- Rx
- Center
- CDER
- Patents
- None listed
Exclusivity & patent cliffs
Protection horizon
Reference approval
Approval date of the reference amivantamab and hyaluronidase-lpuj product.
5 mo ago
amivantamab and hyaluronidase-lpuj: frequently asked questions
Reference exclusivity, biosimilars, interchangeability, and patents for this molecule, from the FDA Purple Book.
Built from official FDA Purple Book records (monthly downloads, the Advanced Search interface, and the published Patent List), with reference-product, license-type, and exclusivity context for amivantamab and hyaluronidase-lpuj.
Related FDA reference tools
- FDA Orange BookApproved drugs, generics, therapeutic-equivalence codes, patents, and exclusivity.
- FDA BiosimilarsFDA-approved biosimilars and interchangeable biosimilars, by reference product.
- 510(k) Predicate DatabaseSearch FDA 510(k) clearances and map predicate-device lineage.
- FDA 483 DatabaseFDA Form 483 observations and inspection records by firm, date, and citation.
